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Key points:  
• GATA-2 expression is restricted to HSPCs, leading to deficiency of NK cell 
progenitors in patients with GATA2 mutation. 
• A long-lived or self-renewing pool of adaptive NK cells can persist in patients with 
GATA2 mutation. 
  
2
Abstract 
Heterozygous GATA2 mutation is associated with immunodeficiency, lymphedema, and 
myelodysplastic syndrome. Disease presentation is variable, often coinciding with loss of 
circulating dendritic cells, monocytes, B cells, and NK cells. Nonetheless, in a proportion of 
patients carrying GATA2 mutation, NK cells persist. We found that peripheral blood NK cells 
in symptomatic patients uniformly lacked expression of the transcription factor PLZF, as well 
as expression of intracellular signaling proteins FcεRγ, SYK, and EAT-2 in a variegated 
manner. Moreover, consistent with an adaptive identity, NK cells from patients with GATA2 
mutation displayed altered expression of cytotoxic granule constituents and produced IFN-γ 
upon Fc-receptor engagement but not following combined IL-12 and IL-18 stimulation. 
Canonical, PLZF-expressing NK cells were retained in asymptomatic carriers of GATA2 
mutation. Developmentally, GATA-2 was expressed in hematopoietic stem cells, but not in 
NK cell progenitors, CD3–CD56bright, canonical or adaptive CD3–CD56dim NK cells. Peripheral 
blood NK cells from individuals with GATA2 mutation proliferated normally in vitro, whereas 
lineage negative progenitors displayed impaired NK cell differentiation. In summary, adaptive 
NK cells can persist in patients with GATA2 mutation, even after NK cell progenitors expire. 
Moreover, our data suggests that adaptive NK cells are more long-lived than canonical, 
immunoregulatory NK cells. 
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INTRODUCTION 
Loss-of-function mutations in GATA2 are associated with an autosomal dominant, typically 
adult-onset syndrome with variable clinical presentation, yet high mortality.1,2 Patients may 
present with severe mycobacterial, papilloma virus and herpes virus family infections, 
lymphedema, hypocellular bone marrow failure or myelodysplastic syndrome (MDS) evolving 
to acute myeloid leukemia (AML).3-9 GATA-2 is a transcription factor required for 
hematopoietic stem and progenitor cell (HSPC) survival and proliferation.10,11 GATA-2 
haploinsufficiency generally manifests in a progressive loss of monocytes, dendritic cells, B 
cells and natural killer (NK) cells, leading to increased susceptibility to certain infections.3,4,12-
14
 Reduction of monocyte, B cell as well as CD4+ T cell numbers is associated with 
symptomatic disease, whereas cytotoxic effector CD8+ T cell numbers generally persist.1,2 
Remarkably, an index case of selective NK cell-deficiency associated with severe herpes 
virus infections including varicella, cytomegalovirus (CMV), and herpes simplex virus 
(HSV),15 was later found to harbor a heterozygous GATA2 mutation.16 With respect to NK 
cells, GATA2 mutation is associated with a loss of CD3–CD56bright NK cells, whereas 
differentiated CD3–CD56dim NK cell curiously persist in some patients.1,16 
NK cells are lymphocytes that act at the interface between innate and adaptive 
immunity.17 They can eradicate infected and neoplastic cells, as well as autologous activated 
immune cells, by targeted release of cytotoxic granules containing perforin and granzymes. 
Moreover, NK cells can relay signals to other immune cells, producing interferon (IFN)-γ in 
response to target cells or combinations of exogenous cytokines such as interleukin (IL)-2, 
IL-12, IL-15, and IL-18.18,19 Besides GATA2, one other gene defect has hitherto been 
associated with human NK cell-deficiency. Autosomal recessive missense mutations in 
MCM4, encoding a component of the minichromosome maintenance (MCM) complex 
essential for genomic DNA replication, are associated with selective loss of the CD3–CD56dim 
NK cell subset accompanied by an increase in relative frequencies of peripheral blood CD3–
CD56bright NK cells.20 The loss of mature, cytotoxic CD3–CD56dim NK cells in cases of MCM4-
deficiency thus contrasts GATA-2 haploinsufficiency, where seemingly differentiated NK cells 
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may persist in the absence of assumed precursor CD3–CD56bright NK cells.1,16 These and 
other observations21 thus question established NK cell developmental relationships.22 
Recent studies of murine CMV infection have revealed that NK cells responding to 
infection can expand and persist.23 Such cells display features of adaptive T and B cells, 
including lasting expansions of cells that can undergo robust recall responses. In humans, 
we and others have uncovered CMV-associated NK cells with epigenetic similarities to 
cytotoxic effector CD8+ T cells. These so-called adaptive NK cells display characteristic DNA 
methylation-dependent silencing of the transcription factor PLZF, as well as stochastic loss of 
expression of membrane proximal signaling molecules FcεRγ, SYK, or EAT-2.24,25 
Importantly, revealing a dichotomy in NK cell function, such adaptive NK cells have a 
markedly reduced capacity for immunoregulatory killing of autologous activated T cells and 
lack responsiveness to IL-12 and IL-18.24,26 Notably, experiments in mice and observations in 
humans indicate that adaptive NK cells provide protective immunity to CMV.23,27 In humans, 
they mediate strong Fc receptor-dependent effector functions,24,25 ostensibly contributing to 
cross-protective antibody-mediated immunity. The molecular mechanisms of adaptive NK 
cell development and homeostasis are poorly understood.28 
 Here, we have explored NK cell phenotype and function in asymptomatic and 
symptomatic individuals with GATA2 mutation. Remarkably, we find that NK cells persisting 
in symptomatic individuals uniformly display phenotypic and functional attributes of adaptive 
NK cells. The results provide clues to NK cell ontogenetic relationships and raise questions 
regarding the pathogenesis of GATA-2 haploinsufficiency. 
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METHODS 
Blood samples, cells, and antibodies 
Sample collection was carried out via protocols approved by the Regional Ethical Review in 
Stockholm, as well as the Institutional Review Boards in Newcastle upon Tyne, UK and the 
National Institutes of Health, MD, USA. Written informed consent was obtained from all 
individuals. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation (Lymphoprep, Axis-Shield), cryopreserved, and resuspended in complete 
medium (RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, penicillin, and 
streptomycin; all Hyclone). 
 For cell lines and antibodies, see the Online Supplemental Data. 
 
Flow cytometry 
For phenotypic analyses, PBMC were surface stained with fluorochrome-conjugated 
antibodies as indicated and a fixable dead cell stain (Invitrogen), fixed in 2% formaldehyde 
(Polysciences) in PBS, and permeabilized in 0.05% Triton X-100 (Sigma-Aldrich) in PBS for 
intracellular staining. For functional analyses, lymphocytes were stimulated, surface stained 
with antibodies and a fixable dead cell stain, as previously described.24,29 In experiments 
measuring cytokine production, GolgiPlug (BD Bioscience) was added during stimulation. 
Flow cytometry data acquisition and analyses are detailed in the Online Supplemental Data.  
 
Transcription factor cloning and interaction studies 
See Online Supplemental Data. 
 
Ex vivo NK cell expansions 
See Online Supplemental Data.  
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RESULTS 
Predominance of NK cells lacking PLZF expression in patients with heterozygous GATA2 
mutation 
Previous reports of patients with heterozygous GATA2 mutation have described 
heterogeneity in NK cell numbers, with some individuals having high frequencies of 
differentiated peripheral blood NK cells despite loss of less mature CD3–CD56bright cells.1,16 
Sparked by the characterization of long-lived NK cells in mice,23 we hypothesized that 
residual NK cells in human patients with bone marrow failure might constitute adaptive cells. 
We analyzed ten adult patients with GATA2 mutation and clinical manifestations, in addition 
to three asymptomatic adult carriers (Table 1). As expected, most patients had markedly 
elevated levels of circulating FLT-3 ligand, and markedly reduced but heterogeneous 
peripheral blood B cell, monocyte and NK cell counts (Table 1). Relative to healthy controls, 
absolute numbers of CD3–CD56+/CD16+ NK cells among lymphocytes were low in the 
majority of patients and in all asymptomatic carriers (Figure 1A). The majority of patients 
displayed reduced frequencies of CD3–CD56bright NK cells, as previously described,1,16,30 
whereas asymptomatic carriers maintained these cells (Figure 1B; Table S1, Table S2). Of 
note, 4/6 GATA2 mutated patients and asymptomatic carriers retaining CD3–CD56bright NK 
cells were CMV seronegative with the remaining 2 having unknown CMV status at the time of 
blood collection (Figure 1B).  
CMV-associated adaptive NK cells have been defined as CD57+NKG2C+ NK cells.31 
Frequencies of CD57-expressing CD3–CD56dim NK cells were elevated in patients with 
GATA2 mutation, but normal in asymptomatic carriers (Figure 1C, Table S1, Table S2). 
Three patients displayed exceedingly high frequencies of NKG2C-expressing CD3–CD56dim 
NK cells (Figure 1D). However, several patients had low frequencies of NKG2C-expressing 
NK cells, including a CMV seropositive patient. Asymptomatic carriers also displayed low 
frequencies of NKG2C-expressing NK cells, consistent with at least two of these individuals 
being CMV seronegative. As such, high proportions of adaptive CD57+NKG2C+ NK cells are 
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found in some patients, but data do not strongly indicate an increased prevalence of adaptive 
NK cells in patients with GATA2 mutation.  
We and others recently reported that CMV-associated human adaptive NK cells may 
lack expression of NK cell signaling proteins FcεRγ, SYK, and EAT-2, whereas lack of the 
transcription factor PLZF generally defines such cells.24,25 Accordingly, adaptive NK cells do 
not necessarily express NKG2C or CD57.24,28 High frequencies of CD3–CD56dim NK cells 
variably lacking expression of the signaling molecules FcεRγ, SYK, or EAT-2 were a feature 
of patients with GATA2 mutation, but not asymptomatic carriers (Figure 1E-G). Strikingly, 
PLZF-expressing CD3–CD56dim NK cells were profoundly reduced or absent in 7 of 10 
GATA2 patients (Figure 1H). In these patients, PLZF– subsets constituted the entire NK cell 
compartment. In contrast, asymptomatic carriers displayed PLZF expression patterns 
comparable to healthy controls. Altogether, patients with GATA2 mutation displayed very 
high frequencies of NK cells lacking expression of one or more of signature signaling 
proteins (Figure 1I). In individuals with GATA2 mutation, lack of PLZF expression in CD56dim 
NK cells correlated with loss of CD56bright NK cells and severe disease (Figure 1J). In 
contrast, PLZF expression among CD56dim NK cells and the frequency of CD56bright NK cells 
was not generally correlated among healthy controls (Figure 1K). However, when examined 
solely among individuals with sizeable expansions of adaptive NK cells, lack of PLZF 
expression among CD56dim NK cells correlated with reduced CD56bright NK cell frequencies 
(Figure 1L). Together, these results suggest that NK cells with an adaptive phenotype may 
selectively persist in patients with GATA2 mutation. 
 
Additional phenotypic features of adaptive NK cells in patients with GATA2 mutation 
NK cell surface receptor phenotype has previously been examined in limited numbers of 
GATA2 patients.1,16 To substantiate the notion of persistent differentiated, adaptive NK cells, 
we examined the expression of NKG2A, CD85j, CD161, CD7, and CD2, variably expressed 
on canonical and adaptive NK cells.24 Patients exhibited dichotomous expression patterns for 
NKG2A, whereas asymptomatic carriers displayed frequencies of NKG2A+ CD3–CD56dim NK 
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cells similar to healthy controls (Figure 2A; Table S1, Table S2). Furthermore, expression of 
CD85j was elevated on CD3–CD56dim NK cells from patients, but not asymptomatic carriers 
(Figure 2B). Additionally, we observed significantly lower frequencies of CD3–CD56dim NK 
cells in patients expressing CD161 and high levels of CD7, as well as a trend of higher 
frequencies of cells expressing CD2 (Figure 2C-E; Figure S1). A single CMV seropositive 
GATA2 mutated patient displayed NK cells with unusually low levels of CD2. These cells 
were CD3–CD56+/–CD16+/–CD57+FcεRγ–SYK–EAT-2+PLZF–CD2–NKG2A+NKG2C–
CD85j+CD161+. In summary, peripheral blood NK cells from patients, but not asymptomatic 
carriers, expressed an adaptive NK cell surface receptor phenotype. The enrichment of NK 
cells with an adaptive phenotype did not strictly correlate with CMV seropositivity. 
 In a previous report assessing the phenotype of NK cells in patients with GATA2 
mutation, reduced CD16 expression levels on CD3–CD56dim NK cells was noted.1  Similarly, 
we found high frequencies of CD3–CD56dimCD16– NK cells in three out of ten patients with 
GATA2 mutation (Figure 2F). However, we also noted expansions of CD3–CD56–CD16+ 
cells expressing multiple NK cells markers in patients with GATA2 mutation (Figure 2G-I). 
Expansions of such NK cells, which are generally poorly cytotoxic and demonstrate 
attenuated cytokine production, were originally described in settings of chronic viral infection 
such as human immunodeficiency virus (HIV)-1.32,33 Our observations thus indicate a high 
level of immune activation in several patients with GATA2 mutation, consistent with the 
severe persistent viral infections often observed upon development of cellular deficiencies. 
 
Patients with GATA2 mutation display an altered cytotoxic granule content associated with 
adaptive NK cell differentiation 
In terms of global DNA-methylation, adaptive NK cells epigenetically approximate effector 
CD8+ αβT cells.24 While allelic silencing of B and myeloid cell signaling molecules imprint 
major functional changes, adaptive NK cell differentiation is also accompanied by more 
subtle changes in protein expression. NK cells and cytotoxic T lymphocytes (CTL) employ 
the same machinery for target cell killing, yet relative expression levels of granule 
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constituents differ.29 Investigating healthy CMV seropositive donors (n=16) with sizeable 
adaptive NK cell populations by intracellular flow cytometry, we found that adaptive PLZF– as 
compared to canonical PLZF+ NK cells display lower expression of perforin and granzyme A 
and increased expression of granzyme B (Figure 3A; Figure S2A). As such, expression 
levels of granzyme A and B in adaptive NK cells approximated those of CD3+CD8+CD57+ 
CTL. Expression of perforin and granzyme A was decreased and granzyme B increased in 
bulk CD3–CD56dim NK cells from patients, but not asymptomatic carriers (Figure 3B; Figure 
S2A), thus demonstrating a similar pattern of cytotoxic granule protein expression observed 
in adaptive NK cells. 
 The expression of cytotoxic granule constituents is controlled, among others, by the 
T-box transcription factors T-bet and Eomesodermin (Eomes).34 T-bet and Eomes 
expression in healthy CMV seropositive donors with sizeable pools of adaptive NK cells as 
well as in individuals with GATA2 mutation was examined by flow cytometry. Expressed in all 
NK cell subsets (Figure S2A), levels of T-bet were significantly lower in adaptive CD3–
CD56dimPLZFlow/– NK cells compared to canonical CD3–CD56dimPLZF+ NK cells, approaching 
those of CD3+CD8+CD57+ CTL (Figure 3C). Eomes expression displayed a greater variance 
than T-bet, with no significant differences between NK cell subsets (Figure 3C). Expression 
of T-bet was reduced in CD3–CD56dim NK cells from patients with GATA2 mutation, but not 
asymptomatic carriers, while Eomes levels did not significantly differ (Figure 3D). Overall, 
expression of T-bet and Eomes was positively correlated with expression of perforin and 
granzyme A, whereas expression of T-bet was negatively correlated with expression of 
granzyme B (Figure 3B, D, and Figure S2B, C). Thus, human adaptive NK cells display an 
expression pattern of granule constituents reminiscent of CTL, corresponding to decreased 
expression of T-bet relative to canonical CD3–CD56dim NK cells. In agreement with the 
dramatically increased frequencies of NK cells with adaptive features in patients with GATA2 
mutation, expression of perforin and T-bet were reduced in the CD3–CD56dim NK cells from 
these patients. 
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Residual NK cells from patients with GATA2 mutations display functional characteristics of 
adaptive NK cells 
Although adaptive NK cells diversify with respect to surface and intracellular signaling protein 
expression, they display specific functional attributes.26 Adaptive NK cells do not kill activated 
autologous T cells or produce IFN-γ in response to innate cytokines IL-12 and IL-18.24 To 
determine if NK cells in patients with GATA2 mutation also functionally resembled CMV-
associated adaptive NK cells in healthy donors, PBMC from healthy controls and individuals 
carrying GATA2 mutation were stimulated with a combination of IL-12 and IL-18. While NK 
cells from healthy controls as well as asymptomatic carriers of GATA2 mutation produced 
IFN-γ, cells from GATA2 patients did not (Figure 4A). Generally, the frequency of CD3–
CD56dim NK cells expressing PLZF correlated with the frequency of IFN-γ producing cells 
(Figure S3A). Furthermore, patients with GATA2 mutation retained PLZF-expressing innate 
mucosal associated invariant T (MAIT) cells that produced IFN-γ following IL-12 and IL-18 
stimulation (Figure S3B), demonstrating a selective defect in the NK cell compartment of 
patients with GATA2 mutation. 
 Adaptive NK cells maintain Fc receptor expression and respond to antibody-coated 
target cells. With respect to responses triggered by Fc receptor engagement, NK cells from 
patients with GATA2 mutation retained the capacity to degranulate and produce IFN-γ and 
TNF (Figure 4B-D). Together, the data demonstrate that PLZF-deficient NK cells persisting 
in patients with GATA2 mutation display functional attributes associated with adaptive NK 
cells in healthy individuals.  
 
GATA-2 is expressed in hematopoietic stem and progenitor cells but not in NK cell 
progenitors or differentiated cells 
GATA-2 is required for survival and proliferation of HSPCs35 and, interestingly, has been 
reported to bind PLZF.36 We confirmed this biochemical interaction by transient transfection 
of 293T cells with constructs encoding tagged transcription factors (Figure 5A). GATA-2 
immunoprecipitation resulted in co-immunoprecipitation of PLZF. Similarly, 
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immunoprecipitation of GATA-3, which is expressed in human peripheral blood NK cells,37 
also resulted in co-immunoprecipitation of PLZF. Given that Western blots suggest weak 
expression of GATA-2 in CD3–CD56bright NK cells,16 PLZF and GATA-2 could potentially 
regulate NK cell differentiation co-operatively. We performed intracellular stainings for PLZF, 
GATA-2 as well as GATA-3 along with staining for the CD34+ hematopoietic stem and 
progenitor cell, lineage, and NK cell differentiation markers on adult bone marrow and 
peripheral blood from healthy individuals (Figure 5B-D). As multi-parameter SNE and two-
parameter plots reveal, GATA-2 was expressed in CD34+ HSPCs in blood and bone marrow, 
but not in CD3–CD56bright or CD3–CD56dim NK cells found in any compartment (Figure 5C, D). 
Early CD34+ NK cell progenitors have been associated with acquisition of CD10 and 
CD45RA expression, as well as increased CD38 expression.38,39 Although GATA-2 
expression correlated with that of PLZF, expression of CD10, CD45RA, and CD38 was 
associated with an absence of GATA-2 expression (Figure 5B), indicating that GATA-2 is 
expressed in CD34+ HSPC, but not in committed NK cell progenitors. In contrast, GATA-3 
was uniformly expressed in peripheral blood NK cells with higher expression in CD56bright 
compared to CD56dim NK cells (Figure 5D), and may therefore constitute an interaction 
partner of PLZF in mature NK cells. 
 
Impaired NK cell differentiation from lineage negative cells in individuals with GATA2 
mutation 
To further understand the impact of GATA-2 haploinsufficiency on NK cell differentiation and 
proliferation, we adopted an ex vivo NK cell expansion method with the potential to expand 
NK cell progenitors from the blood.40,41 Blood samples from healthy controls and from seven 
individuals with heterozygous GATA2 mutation were studied (Table S3). Sorted total NK 
(CD3–CD20–CD14– and CD16+ and/or CD56+) cells or lineage negative (Lin–; CD3–CD20–
CD14–CD16–CD56–) cells were cultured for 14 days at which time phenotyping and resorting 
was performed. The Lin– cell population contains circulating CD34+ HSPC which encompass 
stage 1 and 2 NK cell progenitors, as well as low frequencies of CD34–CD117+CD161+CD94– 
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stage 3 and CD94+ stage 4-like NK cell progenitors (Figure S4).38 Freshly sorted total NK 
cells and Lin– cells from patients and healthy controls showed comparable 14-day overall 
expansion kinetics in the presence of B-LCL feeder cells and IL-2 (Figure 6A), suggesting 
that GATA-2 haploinsufficiency did not markedly impair cell proliferation. However, there 
were differences in the type of cells produced. Total NK cells from controls produced 
primarily CD16+CD56+ and a smaller population of CD16–CD56+ after 14 days of expansion 
culture. In contrast, total NK cells expanded from GATA2+/mut patients (mutation affecting 
coding sequence or exon-intron splice sites) produced significantly reduced numbers of 
CD16–CD56+ cells, while expansion of total NK cells from GATA2+/i5 patients (intronic 
mutation in intron 5) resulted in more variable proportions of CD16–CD56+ cells after 
expansion (Figure 6B, C). Sorted Lin– cells from healthy controls generated a significant 
CD56+ (either CD16dimCD56+ or CD16–CD56+) cell population at day 14 (Figure 6B, D), 
indicating the presence of progenitors for CD56+ NK cells within the Lin– cell population. Re-
sorting and re-stimulation of control Lin– cells after the first 2 weeks of culture consistently 
generated more CD56+ NK cells at day 28 (Figure 6B, E). In contrast, Lin– cells from 
GATA2+/mut patients failed to generate CD56+ NK cells at day 14 or day 28 (Figure 6B, E), 
consistent with a diminished frequency of Lin–CD34–CD117+CD161+CD94– NK cell 
progenitors (Figure S4C). Lin– cells from GATA2+/i5 patients generated variable numbers of 
CD56+ NK cells at day 14, with a trend toward fewer CD16–CD56+ cells at day 28 (Figure 
6B, D). Finally, corroborating our flow cytometry stainings, GATA2 transcription was detected 
in Lin– cells, but not in CD3–CD16–CD56+ NK cells (Fig. 6F). Our findings indicate that the NK 
cell progenitor pool is markedly diminished in individuals with GATA2 mutation. 
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DISCUSSION 
Haploinsufficiency of the transcription factor GATA-2 causes HSPC attrition, leading to 
deficiencies in monocytes, dendritic cells (DC), B cells, and NK cells and precipitating clinical 
symptoms of immunodeficiency, lymphedema as well as MDS.1,2 An estimated 20% of 
individuals with GATA2 mutation and lymphopenias retain NK cells.1,16 We determined that 
GATA-2 is expressed in HSPC, but not in committed NK cell progenitors. Rather, CD56bright 
and CD56dim NK cells expressed GATA-3. A previous study reported a paucity of B/NK cell 
progenitors in patients with GATA2 mutation,14 and our culture system failed to generate NK 
cells from Lin– progenitor cells in such patients. Performing a variety of phenotypical and 
functional assays, we found that NK cells in such patients overwhelmingly displayed features 
of adaptive NK cells.26,28 Specifically, they lacked expression of PLZF, displayed distinct, 
clonal-like yet variable expression patterns of surface receptors and signaling proteins, 
expressed levels of cytotoxic granule contents associated with adaptive NK cells and CTL, 
and did not produce IFN-γ in response to IL-12 and IL-18. Such extreme biases in the NK 
cell population towards adaptive phenotypes have not been observed in healthy individuals.24 
Remarkably, such differentiated NK cells persisted in the apparent absence of progenitors, 
akin to CMV-induced adaptive NK cells in mice.23. 
The molecular mechanisms of adaptive NK cell differentiation and homeostasis are 
poorly defined.28 The fact that adaptive NK cells comprised the total residual NK cell 
population in symptomatic patients with heterozygous GATA2 mutation could be the result of 
either sustained output of adaptive NK cells due to developmental pathways less dependent 
on GATA-2 or, following depletion or dysfunction of the myeloid and lymphoid progenitor cell 
pool, peripheral survival and proliferation of adaptive NK cells. GATA-2 binds a promoter 
element of Nfil3, encoding a transcription factor that promotes cell survival.42-44 Nfil3-deficient 
mice display a severe defect in NK cell development,45,46 in addition to impaired development 
of CD8+ and CD103+ conventional DC subsets, B cells, and other innate lymphoid 
subsets.44,47-49 Reduced GATA-2-mediated induction of NFIL-3 could thus contribute to DC, B 
cell and NK cell cytopenias observed in humans with GATA-2 haploinsufficiency, as 
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suggested by our findings of reduced NK cell output from Lin– cell progenitors in patients with 
GATA2 mutation. Interestingly, CMV infection bypasses the requirement for Nfil3 in mouse 
NK cell development, supporting generation of long-lived, adaptive NK cells.50 Moreover, in 
mice, Nfil3 is required for the development of Eomes-expressing NK cells, but not liver or 
salivary gland NK cells that are TRAIL+Eomes–.51-53 Conceivably, GATA-2 haploinsufficiency 
in humans could thus bias for GATA-2-independent differentiation and expansion of adaptive 
NK cells. However, patients with GATA2 mutation generally present with severe infections, 
yet a majority lack sizeable peripheral numbers of inflammation-driven adaptive NK cells,1,16 
similar to most healthy adults.24 We thus interpret our data as supporting a requirement for 
GATA-2-expressing hematopoietic stem and progenitor cells and canonical CD56dim NK cell 
progenitors for initial development of adaptive NK cells (Figure S5). Once hematopoietic 
progenitor deficiencies develop in patients with GATA2 mutation, adaptive NK cell 
differentiation may also be limited by reduced numbers of accessory immune cells. In 
settings of HSPC transplantation, monocytes are required for adaptive NK cell 
differentiation.54 
Deutrium-labelling experiments in healthy adults have indicated a 14-day half-life of 
blood NK cells.55 Prolonged survival and self-renewal could explain the vast 
overrepresentation of adaptive NK cells observed in patients with GATA2 mutation. 
Supporting this notion, human adaptive NK cells express higher levels of anti-apoptotic Bcl-2, 
with epigenetically unique populations persisting for at least 35 months.24,56 PLZF has been 
demonstrated to confer a pro-apoptotic phenotype to iNKT and MAIT cells.57 Accordingly, 
iNKT precursors in Itk-deficient mice with elevated levels of PLZF, EOMES, CD122 display 
increased rates of apoptosis.58 Reduced expression of PLZF could thus support adaptive NK 
cell longevity, explaining the persistence of adaptive NK cells in symptomatic individuals with 
GATA2 mutation devoid of canonical NK cell progenitors. IL-15-dependent self-renewal 
maintains CD8+ T cell memory.59,60 Homeostatic proliferation may also contribute to adaptive 
NK cell persistence, although only low level Ki-67 expression is detected in these cells (data 
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not shown). Moreover, in vitro culture experiments suggested a diminished proliferative 
capacity of NK cells from patients with GATA2 mutation. 
Although PLZF interacts with GATA-2,36 our findings argue against GATA-2/PLZF co-
operativity in progenitors and differentiated NK cells, as GATA-2 expression was confined to 
HSPCs. CMV establishes life-long latency in CD34+ cells and myeloid progenitors and 
expression of CMV latency-associated genes is, at least partially, GATA-2-dependent.61 
Latency is maintained by suppression of miR-92a leading to up-regulation of GATA-2, 
promoting IL-10 production that inhibits T cell immunity and stem cell apoptosis.61 
Hypothetically, CMV-infected individuals with heterozygous GATA2 mutation may have 
impaired IL-10 induction, contributing to an inflammatory milieu driving stem cell exhaustion. 
Infections in general and CMV in particular could thus play a role in the pathology of GATA2 
haploinsufficiency. 
With respect to disease, it is not clear if adaptive NK cells may protect, e.g. by 
counteracting viral infections, or promote progression. Emergence of CMV-associated 
adaptive NK cells may protect from virus reactivation. Through strong Fc receptor CD16-
mediated effector responses, adaptive NK cells may even increase antibody-dependent 
resistance to other intracellular infections.24,25 However, adaptive NK cells are major 
producers of pro-inflammatory mediators IFN-γ and TNF, cytokines that have been shown to 
promote HSPC differentiation and exhaustion during stress or demand-adapted 
hematopoiesis, even inducing HSPC destruction by up-regulating apoptosis-related genes 
such as FAS and caspases.62,63 In patients, exacerbated levels of these cytokines may result 
from adaptive NK cell activation or diminished immunoregulation of activated T cells.24 As 
such, while beneficial for killing of infected cells, high frequencies of adaptive NK cells in 
individuals with GATA2 mutation could contribute to progressive, inflammation-driven bone 
marrow failure. Notably, in our limited material, asymptomatic carriers with GATA2 mutation 
were mostly CMV seronegative and retained normal numbers of conventional NK cells while 
several patients had increased frequencies of CD56– NK cells, associated with chronic viral 
infections. 
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In summary, we find that GATA-2 haploinsufficiency is associated with attrition of NK 
cell progenitors, abolishing canonical NK cell differentiation. Nonetheless, adaptive NK cells 
may persist in patients with GATA2 mutation, indicating that they are considerably more 
long-lived than canonical NK cells. Further support for longevity and self-renewal of adaptive 
NK cells comes from studies of paroxysmal nocturnal hemoglobinuria patients, where Corat 
and colleagues document that glycosylphosphatidylinositol (GPI)-expressing adaptive NK 
cells persist in spite of GPI-deficient HSPCs progressively dominating the bone marrow 
(Corat et al, in press, BLOOD, 2017). These findings provide insights to a mechanism that 
may ensure durable anti-viral immunity,28 with potential implications for strategies aimed at 
providing lasting NK cell-based immunotherapy of cancer.64,65  
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FIGURE LEGENDS 
 
Figure 1. High prevalence of NK cells displaying lack of intracellular signaling protein 
and PLZF expression in patients with GATA2 mutation. PBMCs from CMV seronegative 
(n=69 and seropositive (n=127) healthy donors as well as patients (n=10) and asymptomatic 
carriers (n=3) with heterozygous GATA2 mutations were examined by flow cytometry. 
Graphs depict (A) the number of total NK cells as defined by CD3–CD56+/CD16+ cells in the 
lymphocyte gate, (B) the percentage of CD3–CD56bright NK cell within the total CD3–
CD56+/CD16+ NK cell population, and (C) the percentage of CD3–CD56dim NK cells 
expressing CD57. (D-H) Contour plots show CD3–CD56dim NK cells from representative CMV 
seronegative and seropositive healthy donors as well as two patients and one asymptomatic 
carrier with GATA2 mutations. Expression of CD57 is plotted against (D) NKG2C or the 
intracellular proteins (E) FcεRγ, (F) SYK, (G) EAT-2 and (H) PLZF. (D-H) Graphs depict the 
percentages of CD3–CD56dim NK cells expressing NKG2C, FcεRγ, SYK, EAT-2 or PLZF, as 
indicated. In the graphs (A-H) CMV serostatus for GATA2 patients and carriers is indicated 
as seronegative (open circles) seropositive (grey circles) or undetermined (black circles). (A-
H) Boxes indicate 25th, 50th (median) and 75th percentiles, with a plus indicating the mean. 
For box plots, whiskers indicate 95% confidence intervals. Otherwise, error bars indicate 
mean with SD. P-values were determined using Student’s unpaired t-test. * denotes p<0.05, 
** denotes p<0.01, and *** denotes p<0.001. (I) The overall frequency of healthy controls, 
stratified on CMV seropositivity, or individuals with GATA2 mutations with significant, 
sizeable down-regulations of one, two or three of the signaling proteins FcεRγ, SYK, and 
EAT-2 is plotted. (J) In individuals with GATA2 mutation, the percentage of CD3–CD56bright 
NK cell within the total CD3–CD56+/CD16+ NK cell population is plotted as a function of the 
frequency of PLZF expressing CD3–CD56dim NK cells. (K) Among healthy controls, the 
percentage of CD3–CD56bright NK cell within the total CD3–CD56+/CD16+ NK cell population is 
plotted as a function of the frequency of PLZF expressing CD3–CD56dim NK cells. The CMV 
serostatus is indicated as seronegative (open circles) seropositive (grey circles). (L) Among 
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healthy controls with sizeable adaptive NK cell expansions as defined by PLZF-deficiency, 
the percentage of CD3–CD56bright NK cell within the total CD3–CD56+/CD16+ NK cell 
population is plotted as a function of the frequency of PLZF-expressing CD3–CD56dim NK 
cells. Healthy controls with sizeable adaptive NK cell expansions were overwhelmingly CMV 
seropositive (grey circles). 
 
Figure 2. Surface receptor expression patterns associated with adaptive NK cells in 
patients with GATA2 mutation. PBMCs from CMV seronegative (n=12) and seropositive 
(n=26) healthy donors as well as patients (n=10) and asymptomatic carriers (n=3) with 
heterozygous GATA2 mutations were examined by flow cytometry. Graphs depict the 
percentages of CD3–CD56dim/CD16+ NK cells expressing expressing (A) NKG2A, (B) CD85j, 
(C) high levels of CD7, (D) CD161, (E) CD2, (F) CD16, and (G) CD56. CMV serostatus for 
GATA2 patients and carriers is indicated as seronegative (open circles) seropositive (grey 
circles), or undetermined (black circles). Boxes indicate 25th, 50th (median) and 75th 
percentiles, with a plus indicating the mean. For box plots, whiskers indicate 95% confidence 
intervals. Otherwise, error bars indicate mean with SD. P-values were determined using 
Student’s unpaired t-test. * denotes p<0.05, ** denotes p<0.01, and *** denotes p<0.001. (H, 
I) Contour plots show CD56 and CD16 expression on CD3– lymphocytes on representative 
CMV seropositive healthy donors with adaptive NK cell expansions as well as two selected 
patients with heterozygous GATA2 mutation and high frequencies of CD3–CD16+CD56– NK 
cells. Plots gated on CD3–CD16+/CD56+ NK cells depict CD56 versus NKp46, FcεRγ, PLZF, 
CD57, NKG2A, T-bet, and Eomes expression. 
 
Figure 3. Cytotoxic granule constituent and T-bet expression pattern resembling 
adaptive NK cells in patients with GATA2 mutation. PBMCs healthy donors and 
individuals with heterozygous GATA2 mutations were examined for expression of cytotoxic 
granule constituents perforin, granzyme A (GzmA) and granzyme B (GzmB) as well as the 
transcription factors T-bet and Eomes by intracellular flow cytometry. Expression is shown as 
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median fluorescence intensity (R-MFI) relative to CD3+CD8+CD57+ T cells in the same 
sample. (A) The graph depicts expression of perforin, granzyme A and B in conventional 
PLZF+ (open circles) and adaptive PLZF– (filled circles) CD3–CD56dim NK cells from healthy 
adult CMV-seropositive donors (n=16) with sizeable pools of adaptive NK cells. (B) The 
graphs depict perforin, granzyme A and B expression in CD3–CD56dim NK cells from healthy 
CMV-seronegative (n=6) and seropositive donors (n=6), as well as patients (n=8) or 
asymptomatic carriers (n=2) with GATA2 mutation. (C) The graph depicts expression of T-
bet and Eomes in conventional PLZF+ (open circles) and adaptive PLZF– (filled circles) CD3–
CD56dim NK cells from healthy adult CMV-seropositive donors with sizeable pools of adaptive 
NK cells (n=16). (D) The graphs depict T-bet and Eomes expression in CD3–CD56dim NK 
cells from healthy CMV-seronegative (n=6) and seropositive donors (n=6), as well as 
patients (n=6) or asymptomatic carriers (n=2) with GATA2 mutation. Mean is indicated, with 
error bars representing SD. P-values were determined using Student’s (A, C) paired and (B, 
D) unpaired t-test. ** denotes p<0.01 and *** denotes p<0.001. 
 
Figure 4. Functional properties resembling those of adaptive NK cells in patients with 
GATA2 mutation. PBMCs from healthy donors, CMV seronegative (n=3) or seropositive 
selected for individuals with sizeable expansions of adaptive NK cells (n=6), as well as 
patients (n=4 or n=8) and asymptomatic carriers (n=2; asymptomatic carriers 1 and 2) with 
heterozygous GATA2 mutations were rested over night, stimulated and examined for 
functional responses by flow cytometry. (A) Rested PBMCs were incubated for 24 hours in 
cell culture medium only or in medium supplemented with IL-12 (10 ng/ml) and IL-18 (100 
ng/ml). Histograms show intracellular IFN-γ expression after culture in medium only (filled 
histograms) or IL-12 and IL-18 (open histograms). Graphs depict frequencies of CD3–
CD56dim NK cells expressing IFN-γ. Data from patients 2, 4, 6, and 8 is depicted. (B-D) 
PBMCs were co-cultured with P815 target cells in the presence of 2 μg/ml isotype control 
IgG (cIgG; filled histograms) or anti-human CD16 (CD16; open histogram) monoclonal 
antibodies for 6 hours followed by flow cytometric analysis. Histograms show expression of 
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(B) surface CD107a as well as intracellular (C) IFN-γ or (D) TNF in gated CD3–CD56dim NK 
cells. Graphs depict frequencies of CD3–CD56dim NK cells expressing the indicated functional 
marker. Data from patients 1. 2, 3, 4, 6, 7, 8, and 9 is depicted. 
 
Figure 5. GATA-2 expression is confined to hematopoietic stem and progenitor cells. 
(A) HEK-293T cells were transfected with empty vector (EV), or constructs encoding FLAG-
tagged GATA-2 or GATA-3 and Myc-tagged PLZF. Twenty-four hours after transfection, 
GATA-2 or GATA3 were immunoprecipitated and precipitates as well whole cell lysates were 
analyzed by Western blotting with antibodies, as indicated. (B-D) Bone marrow, cord blood 
or peripheral blood mononuclear cells from healthy volunteers were surface stained with 
antibodies to lineage and differentiation markers and as well as intracellular with antibodies 
to GATA-2, GATA-3 and PLZF. (B) Barnes-Hut t-distributed stochastic neighbor embedding 
(t-SNE) analysis of 13-parametric data was performed on gated CD3–CD14–CD19–CD123–
cells combined from samples of bone marrow (n=2) and peripheral blood of CMV 
seronegative (n=2) and CMV seronegative (n=2) from healthy volunteers. Plots show 
expression of surface and intracellular proteins, as indicated, in the two-dimensional t-SNE 
field with relative expression denoted as red when high and blue when absent. (C) Cell 
density in the t-SNE field for pooled samples from bone marrow (n=2) and peripheral blood 
of CMV seronegative (n=2) and CMV seropositive (n=2) donors, respectively. (D) Contour 
plots show expression of the indicated markers in bone marrow (CD3–CD14–CD19–CD123–) 
Lin–CD34+ cells as well as peripheral blood Lin– lymphocytes. In plots depicting CD56 
expression, dotted lines discriminate CD56bright from CD56dim cells. Plots are from 
representative donors. 
 
Figure 6. Paucity of NK cell progenitors in blood from patients with GATA2 mutation. 
NK cell or CD3–CD20–CD14–CD16–CD56– (Lin–) cell populations were cultured with irradiated 
B-LCL feeder cells and IL-2. (A) Charts depict expansion kinetics of total NK cells and Lin– 
cells up to 14 day of ex vivo expansion. (B) Representative flow plots of control, GATA2 
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exonic/splicing mutation and GATA2 intron 5 mutation. CD16 and CD56 expression on gated 
mononuclear CD3–CD20–CD14–cells is shown. Total NK cells and Lin– cells were sorted and 
cultured separately for 14 days. Lin– cells were sorted and stimulated again from day 14 Lin– 
cells culture for another 14 days (shown as day 28). (C-E) NK cell subpopulations 
frequencies of (C) pre-expansion, day 14 total NK cells, (D) day 14 Lin– cells and (E) day 28 
Lin– cells are shown in comparison. (F) Relative GATA2 expression levels in sorted control 
Lin– cells compared to control CD16–CD56+ cells at day 1 (n=4) and day 14 (n=2) ex vivo 
culture. Bars indicate mean±SD * P<0.05 * P<0.05. ** P<0.01. *** P< 0.01. 
 
Table 1. GATA2 mutations, clinical characteristics, and immunological features of patients. 
Identifier GATA2 cDNA Protein 
Age at 
onset HPV Myco URTI Lung PAP AI MDS 
Lympho
-adema Cancer 
FLT-3 
(pg/ml) 
CMV 
serology 
NK cells 
(cells/μl) 
B cells 
(cells/μl) 
Monocytes 
(cells/μl) 
Patient 1 c.599insG p.G200fs 60 + – + + – – + – – 2662 n.d. 380 114 260 
Patient 2 c.803delG 29 + + + + + – – – – 2096 + 124 16 20 
Patient 3 c.1017+572C>T Intronic 28 + – – – – – + – – 2274 – 10 7 20 
Patient 4 c.1018-1G>T 
p.D340-
381 18 + – + – – + – – – 6874 + 21 71 4 
Patient 5 c.1143+5G>A Splicing 21 + – + + – – – – – n.d.  + 3 3 243 
Patient 6 c.1186C>T p.R396W 7 – + + + – – + – – 1448 + 44 10 0 
Patient 7 c.1186C>T  p.R396W 18 + + + + – – + + – n.d.  – 2 30 0 
Patient 8 c.1187G>A p.R396Q 17 + – – + – – + – – n.d.  + 21 34 0 
Patient 9 c.1192C>T p.R398W ? n.d. – n.d. + + – – – – 3169 n.d. 103 26 800 
Patient 10 c.1193G>A p.R398Q 29 – – + – – – – – – 81 n.d. 207 102 425 
Asympt. carrier 1 c.1017+572C>T Intronic 61 – – – – – – – – –  24 – 128 97 690 
Asympt. carrier 2 c.1017+572C>T Intronic 52 – – – – – – – – – 34 – 106 149 510 
Asympt. carrier 3 c.1193G>A p.R398Q 32 – – – – – – – – – 69 n.d. 10 140 684 
 
A survey of GATA-2 related clinical features of the cohort is presented. HPV (persistent infection of hands, feet, or perineum with HPV); Myco 
(any history of mycobacterial infection); URTI (more than 3 episodes of recurrent bacterial sinusitis, otitis, or other URTI); Lung (loss of lung 
volume or transfer factor ,80% predicted, history of bronchiectasis, chronic bronchitis, more than one episode of pneumonia, radiologically or 
pathologically confirmed pulmonary alveolar proteinosis); AI (autoimmunity: arthritis, panniculitis, or autoimmune cytopenia); MDS (WHO: 
refractory cytopenia with multilineage dysplasia); Lymph (lymphedema); and Cancer (nonhematopoietic malignancy). Positive history: + ; 
Negative history: – ; Not determined: n.d; Deceased:  . Normal cellular ranges were: 126-729 NK cells/μl; 61-321 B cells/μl; and 300-820 
monocytes/μl. 
Figure 1. Schlums, Jung et al.
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